Bioengine Capital Inc. - Net Worth and Insider Trading

Bioengine Capital Inc. Net Worth

The estimated net worth of Bioengine Capital Inc. is at least $0 dollars as of 2024-09-20. Bioengine Capital Inc. is the 10% Owner of Windtree Therapeutics Inc and owns about 0 shares of Windtree Therapeutics Inc (WINT) stock worth over $0. Details can be seen in Bioengine Capital Inc.'s Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Bioengine Capital Inc. has not made any transactions after 2021-12-30 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Bioengine Capital Inc.

Bioengine Capital Inc. Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Bioengine Capital Inc. owns 1 companies in total, including Windtree Therapeutics Inc (WINT) .

Click here to see the complete history of Bioengine Capital Inc.’s form 4 insider trades.

Insider Ownership Summary of Bioengine Capital Inc.

Ticker	Comapny	Transaction Date	Type of Owner
WINT	Windtree Therapeutics Inc	2021-12-30	10 percent owner

Bioengine Capital Inc. Latest Holdings Summary

Bioengine Capital Inc. currently owns a total of 1 stock. Bioengine Capital Inc. owns 0 shares of Windtree Therapeutics Inc (WINT) as of December 30, 2021, with a value of $0.

Latest Holdings of Bioengine Capital Inc.

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
WINT	Windtree Therapeutics Inc	2021-12-30	0	3.27	0

Holding Weightings of Bioengine Capital Inc.

Bioengine Capital Inc. Form 4 Trading Tracker

According to the SEC Form 4 filings, Bioengine Capital Inc. has made a total of 2 transactions in Windtree Therapeutics Inc (WINT) over the past 5 years, including 1 buys and 1 sells. The most-recent trade in Windtree Therapeutics Inc is the sale of 1,377 shares on December 30, 2021, which brought Bioengine Capital Inc. around $2 Million.

Insider Trading History of Bioengine Capital Inc.

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Bioengine Capital Inc. Trading Performance

GuruFocus tracks the stock performance after each of Bioengine Capital Inc.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Bioengine Capital Inc. is 28.37%. GuruFocus also compares Bioengine Capital Inc.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Bioengine Capital Inc. within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Bioengine Capital Inc.'s insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Bioengine Capital Inc.

Average Return

Average return per transaction

Outperforming Transactions

0 out of 1 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	-1.42
Relative Return to S&P 500(%)	-5.66

Bioengine Capital Inc. Ownership Network

Ownership Network List of Bioengine Capital Inc.

No Data

Ownership Network Relation of Bioengine Capital Inc.

Bioengine Capital Inc. Owned Company Details

What does Windtree Therapeutics Inc do?

Who are the key executives at Windtree Therapeutics Inc?

Bioengine Capital Inc. is the 10 percent owner of Windtree Therapeutics Inc. Other key executives at Windtree Therapeutics Inc include director & Chief Executive Officer Craig Fraser , VP & Controller & & CAO Jamie Mcandrew , and SVP & CFO John P. Hamill .

Windtree Therapeutics Inc (WINT) Insider Trades Summary

Over the past 18 months, Bioengine Capital Inc. made no insider transaction in Windtree Therapeutics Inc (WINT). Other recent insider transactions involving Windtree Therapeutics Inc (WINT) include a net purchase of 7,812 shares made by Craig Fraser ,

In summary, during the past 3 months, insiders sold 0 shares of Windtree Therapeutics Inc (WINT) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Windtree Therapeutics Inc (WINT) were sold and 434 shares were bought by its insiders, resulting in a net purchase of 434 shares.

Windtree Therapeutics Inc (WINT)'s detailed insider trading history can be found in Insider Trading Tracker table.

Windtree Therapeutics Inc Insider Transactions

No Available Data

Bioengine Capital Inc. Mailing Address

Above is the net worth, insider trading, and ownership report for Bioengine Capital Inc.. You might contact Bioengine Capital Inc. via mailing address: 7 F., No. 3-2, Park St., Nangang Dist., Taipei F5 11503.

Discussions on Bioengine Capital Inc.

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.